MDCX · XBRL financial data

Medicus Pharma financial statements, every quarter

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MDCX's year ends in late December)

In thousands of dollars	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,365*	2,006	1,440	1,685	2,591*	2,704	4,908
General and administrative	2,220*	3,120	4,577	0	5,200*	5,893	6,571
Total operating expenses	3,585*	5,126	6,016	0	7,791*	8,597	11,479
Operating income (loss)	(3,585)*	(5,126)	(6,016)	(0)	(7,791)*	(8,597)	(11,479)
Interest expense	—	0	0	—	—	375	206
Other income (expense)	49*	24	(160)	(555)	(394)*	(445)	(206)
Income tax expense (benefit)	year only	—	—	—	year only	—	—
Net income (loss)	(3,537)*	(5,102)	(6,176)	(20,936)	(15,067)*	(9,042)	(11,618)
Earnings per share, basic USD per share	—	(0.42)	(0.43)	(1.12)	—	(0.31)	(0.21)
Earnings per share, diluted USD per share	—	(0.42)	(0.43)	(1.12)	—	(0.31)	(0.21)
Weighted average shares, basic thousands of shares	—	12,240	14,284	18,632	—	29,541	55,055
Weighted average shares, diluted thousands of shares	—	12,240	14,284	18,632	—	29,541	55,055

Fiscal quarters (MDCX's year ends in late December)

In thousands of dollars	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	4,164	3,982	9,670	8,662	8,705	6,366	15,174
Total current assets	5,378	5,088	10,997	9,781	9,891	7,283	16,982
Right-of-use asset	269	245	221	196	171	144	117
Total assets	5,647	5,658	11,935	9,978	10,061	7,427	27,116
Accounts payable	1,285	2,035	1,770	2,028	3,435	2,279	6,734
Total current liabilities	2,306	3,336	8,544	10,658	9,938	5,954	10,841
Lease liability, non-current	206	174	142	95	60	24	0
Total liabilities	2,512	3,510	8,686	10,783	10,024	5,999	28,841
Accumulated deficit	(28,904)	(34,006)	(40,182)	(0)	(64,348)	(73,390)	(85,008)
Total stockholders' equity	3,135	—	—	(910)	(68)	1,326	(1,764)
Total liabilities and equity	5,647	5,658	11,935	9,978	10,061	7,427	27,116
Common shares outstanding (cover page) thousands of shares	13,415	13,495	17,816	22,029	39,362	56,658	63,181

Fiscal quarters (MDCX's year ends in late December)

In thousands of dollars	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,537)*	(5,102)	(6,176)	(20,936)	(15,067)*	(9,042)	(11,618)
Stock-based compensation	92*	112	117*	853*	430*	599	1,406*
Net cash from operating activities	(3,192)*	(3,941)	(5,469)*	(6,758)*	(6,609)*	(8,970)	(6,983)*
Net cash from investing activities	0*	—	—	—	0*	—	—
Proceeds from issuing common stock	0*	3,784	6,006*	0*	0*	0	0*
Net cash from financing activities	2,050*	3,759	11,156*	10,371*	6,653*	6,825	25,530*
Net change in cash	(1,142)*	(182)	5,687*	(1,007)*	43*	(2,340)	18,826*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Medicus Pharma	15,174	not reported	(6,983)*	63.2M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.